Vol 16, No 4 (2023)
Case report
Published online: 2024-01-04
Acute kidney injury during DRESS syndrome: a case report and literature review
1
, 1, 2, , 2
, 1, 2, , 2
DOI: 10.5603/rdatf.96925
Renal Disease and Transplantation Forum 2023;16(4):135-141.
Abstract
The article presents a case of a 46-year-old woman hospitalized in the Nephrology Department due to acute kidney injury with concomitant cutaneous manifestations. The patient had a history of deep vein thrombosis, resulting in intestinal resection and ileostomy 6 months before the hospitalization. On admission, the patient presented a widespread erythematous and papular eruption with pruritus, burning sensation, and scaling, involving her whole body and most pronounced on her face. The laboratory tests showed increased levels of liver and cardiac injury markers, as well as kidney dysfunction requiring temporary hemodialysis. A skin biopsy revealed chronic inflammation with abundant eosinophils. Based on these findings, the patient was diagnosed with drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome, likely induced by allopurinol. The article highlights the significance of prompt identification of clinical DRESS features, the variety of which can hinder timely diagnosis and management.
Keywords: Drug Hypersensitivity SyndromeAllopurinol/adverse effectsAcute Kidney Injury/etiologySkin Diseases/etiologyOrgan Specificity
References
- Wolfson AR, Zhou Li, Li Yu, et al. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome Identified in the Electronic Health Record Allergy Module. J Allergy Clin Immunol Pract. 2019; 7(2): 633–640.
- Abdelnabi M, Elmssary M, Sekhon J, et al. Acute onset of fever, eosinophilia, rash, acute kidney injury, and a positive Monospot test in a patient on lamotrigine: DRESS syndrome. Lancet. 2022; 399(10338): 1902.
- Knowles SR, Shapiro LE, Shear NH. Anticonvulsant hypersensitivity syndrome: incidence, prevention and management. Drug Saf. 1999; 21(6): 489–501.
- Husain Z, Reddy BY, Schwartz RA. DRESS syndrome: Part I. Clinical perspectives. J Am Acad Dermatol. 2013; 68(5): 693.e1–14; quiz 706.
- Kardaun SH, Sekula P, Valeyrie-Allanore L, et al. RegiSCAR study group. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol. 2013; 169(5): 1071–1080.
- Kano Y, Shiohara T. The variable clinical picture of drug-induced hypersensitivity syndrome/drug rash with eosinophilia and systemic symptoms in relation to the eliciting drug. Immunol Allergy Clin North Am. 2009; 29(3): 481–501.
- Summary of Recommendation Statements. Kidney Int Suppl (2011). 2012; 2(1): 8–12.
- Maubec E, Wolkenstein P, Loriot MA, et al. Minocycline-induced DRESS: evidence for accumulation of the culprit drug. Dermatology. 2008; 216(3): 200–204.
- Chung WH, Chang WC, Lee YS, et al. Taiwan Severe Cutaneous Adverse Reaction Consortium, Japan Pharmacogenomics Data Science Consortium. Genetic variants associated with phenytoin-related severe cutaneous adverse reactions. JAMA. 2014; 312(5): 525–534.
- Ng CY, Yeh YT, Wang CW, et al. Taiwan Severe Cutaneous Adverse Reaction Consortium. Impact of the HLA-B(*)58:01 Allele and Renal Impairment on Allopurinol-Induced Cutaneous Adverse Reactions. J Invest Dermatol. 2016; 136(7): 1373–1381.
- Konvinse KC, Trubiano JA, Pavlos R, et al. HLA-A*32:01 is strongly associated with vancomycin-induced drug reaction with eosinophilia and systemic symptoms. J Allergy Clin Immunol. 2019; 144(1): 183–192.
- Cho YT, Yang CW, Chu CY. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): An Interplay among Drugs, Viruses, and Immune System. Int J Mol Sci. 2017; 18(6).
- Phillips E, Chung WH, Mockenhaupt M, et al. Drug hypersensitivity: Pharmacogenetics and clinical syndromes. Journal of Allergy and Clinical Immunology. 2011; 127(3): S60–S66.
- Sekiguchi A, Kashiwagi T, Ishida-Yamamoto A, et al. Drug-induced hypersensitivity syndrome due to mexiletine associated with human herpes virus 6 and cytomegalovirus reactivation. J Dermatol. 2005; 32(4): 278–281.
- Descamps V, Brunet‐Possenti F. Association of human herpesvirus 6 infection with drug reaction with eosinophilia and systemic symptoms. Arch Dermatol. 2001; 137(3): 301–304.
- Kano Y, Hiraharas K, Sakuma K, et al. Several herpesviruses can reactivate in a severe drug-induced multiorgan reaction in the same sequential order as in graft-versus-host disease. Br J Dermatol. 2006; 155(2): 301–306.
- Tohyama M, Hashimoto K, Yasukawa M, et al. Association of human herpesvirus 6 reactivation with the flaring and severity of drug-induced hypersensitivity syndrome. Br J Dermatol. 2007; 157(5): 934–940.
- Picard D, Janela B, Descamps V, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): a multiorgan antiviral T cell response. Sci Transl Med. 2010; 2(46): 46ra62.
- Chen YC, Chiu HC, Chu CY. Drug reaction with eosinophilia and systemic symptoms: a retrospective study of 60 cases. Arch Dermatol. 2010; 146(12): 1373–1379.
- Onuma H, Tohyama M, Imagawa A, et al. Japan Diabetes Society Committee on Type 1 Diabetes Mellitus Research, Japanese Dermatological Association. High frequency of HLA B62 in fulminant type 1 diabetes with the drug-induced hypersensitivity syndrome. J Clin Endocrinol Metab. 2012; 97(12): E2277–E2281.
- Lian B, Busmanis I, Lee H. Relapsing Course of Sulfasalazine-Induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Complicated by Alopecia Universalis and Vitiligo. Annals of the Academy of Medicine, Singapore. 2018; 47(11): 492–493.
- Ushigome Y, Kano Y, Ishida T, et al. Short- and long-term outcomes of 34 patients with drug-induced hypersensitivity syndrome in a single institution. J Am Acad Dermatol. 2013; 68(5): 721–728.
- Chen YC, Chang CY, Cho YT, et al. Long-term sequelae of drug reaction with eosinophilia and systemic symptoms: a retrospective cohort study from Taiwan. J Am Acad Dermatol. 2013; 68(3): 459–465.
- Roujeau JC, Haddad C, Paulmann M, et al. Management of nonimmediate hypersensitivity reactions to drugs. Immunol Allergy Clin North Am. 2014; 34(3): 473–87, vii.
- Lin TC, Hung LY, Chen YC, et al. Effects of febuxostat on renal function in patients with chronic kidney disease: A systematic review and meta-analysis. Medicine (Baltimore). 2019; 98(29): e16311.
- Chida R, Hisauchi I, Toyoda S, et al. Impact of irbesartan, an angiotensin receptor blocker, on uric acid level and oxidative stress in high-risk hypertension patients. Hypertens Res. 2015; 38(11): 765–769.
- Dagnon da Silva M, Domingues SM, Oluic S, et al. Renal Manifestations of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome: A Systematic Review of 71 Cases. J Clin Med. 2023; 12(14).
